Jan 16, 2026
What is Bydureon, how does it work, and when is it recommended over first‑line diabetes drugs?
Bydureon (exenatide extended‑release) is a once‑weekly injectable GLP‑1 receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes in adults and certai...